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Nasim ZamaniAbstract
Sulfur mustard is an alkylating substance still regarded as a threat in chemical warfare and terrorism. Lung
parenchymal damage occurs in the most severe inhalational exposures. It accompanies an increased risk of
respiratory tract carcinomas and chronic respiratory sequelae including chronic bronchitis, bronchiectasis,
pulmonary fibrosis, interstitial lung disease, emphysema, and bronchiolitis obliterans. Pirfenidone is an antifibrotic
with anti-inflammatory and anti hydroxyl radical activities which stabilizes pulmonary function in idiopathic
pulmonary fibrosis patients. It can be suggested in chronically exposed soldiers or workers with signs and
symptoms of pulmonary fibrosis to improve their quality of life and even prognosis.
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Sulfur mustard (SM) is an alkylating substance still
regarded as a significant threat in chemical warfare and
terrorism. The organs that are most commonly affected by
mustard are the eyes, skin, and respiratory tract. Even
decades after exposure, severe long-term effects such as
chronic obstructive lung disease, lung fibrosis, eye
problems, abnormal pigmentation of the skin, and various
forms of cancer have been diagnosed in these individuals.
Mustard undergoes intramolecular cyclization to form a
highly reactive sulfonium ion that alkylates sulfhydryl
(−SH) and amino (−NH2) groups. Hoarseness, cough, sore
throat, and chest pressure are common initial complaints,
but lung parenchymal damage only occurs in the most
severe inhalational exposures. Factory workers chronically
exposed to mustard as well as soldiers exposed to it during
chemical wars have been reported to have an increased
risk of respiratory tract carcinomas as well as chronic
respiratory sequelae including chronic bronchitis, bronchi-
ectasis, pulmonary fibrosis, interstitial lung disease,
emphysema, and bronchiolitis obliterans [1].
During world war I, airway injury had been reported
in 75% of those exposed to it [1]. Many Iranian soldiersCorrespondence: nasim.zamani@gmail.com
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reproduction in any medium, provided the or(about 40000 to 50000 during the war between Iran and
Iraq in 1980–88) are also of those currently injured and
have chronic respiratory diseases due to mustard gas [2].
In different studies, the late onset of lung injuries among
Iranian soldiers with wartime exposure to SM has been
reported to be between 42.5% and 95% [1,2]. In a review
performed by Mansour Razavi and colleagues, the preva-
lence of chronic pulmonary complications has been
mentioned to be between 45.8% to 100% in civilian
populations, 42.5% to 95% in veterans, and almost 100%
in the children [3]. The late complications of SM in 600
patients evaluated 19 years after exposure has been
reported 80.7% in another study [4]. In a review done by
Poursaleh and associates, respiratory problems have
been mentioned to be the greatest cause of long-term
disability among the people with combat exposure to
SM [5]. In this study, honeycomb lung pathology as
fibrosis and slightly increased tendency for development
of lung cancer with a latency of 20 years have been
mentioned as two potential chronic complications of SM.
Mild, severe, and focal fibrosis were present in 4.8%,
1.6%, and 4.8% of the patients [6]. The most common
alleged mechanism of such injuries is damaging the
epithelial layer of the lung and airways with subsequent
release of inflammatory mediators [7].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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http://www.darujps.com/content/21/1/13On the other hand, pirfenidone (5-methyl-1-phenyl
H-pyridin-2-one) is a newly discovered antifibrotic with
anti-inflammatory and anti hydroxyl radical activities [8].
Its probable mechanism of act is inhibition of transforming
Growth Factor Beta production. Its anti-inflammatory
effect is probably due to the amelioration of the effect of
Tumor Necrosis Factor Alpha. It has been shown that
pirfenidone stabilizes pulmonary function in idiopathic
pulmonary fibrosis patients [8].
It can be suggested that in the sulfur mustard-exposed
soldiers or the workers who are chronically exposed to
this hazardous material and show signs and symptoms of
pulmonary fibrosis, administration of this medication can
improve their quality of life and even prognosis. This
approach, however, should be reserved for those with
confirmed pulmonary fibrosis and not as a routine
approach for all who have confronted SM. Besides,
prospective case–control studies in this regard are
warranted. Thank you.
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